or Try an Advanced Search...

    Ocular Disease Stocks List

    Symbol Grade Name % Change
    INM F InMed Pharmaceuticals Inc. 0.30
    IONS F Ionis Pharmaceuticals, Inc. 1.90
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Rare Diseases Acromegaly Alcohol Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Cancer Cannabinoid Cannabis Cardiomyopathy Cholesterol Cushing's Syndrome Dermatology Diabetes Disease Disorders Drug Discovery

    Related ETFs - A few ETFs which own one or more of the above listed Ocular Disease stocks.

    Symbol Grade Name Weight
    ARKG D ARK Genomic Revolution Multi-Sector ETF 4.2
    MEDX D Horizon Kinetics Medical ETF 2.81
    MNTL B Tema Neuroscience and Mental Health ETF 2.78
    HRTS C Tema Cardiovascular and Metabolic ETF 2.5
    HELX D Franklin Genomic Advancements ETF 2.15
    View all Ocular Disease ETFs...
    Compare ETFs
    Compare ARKG to HELX Compare ARKG to HRTS Compare MEDX to HELX

        Ocular Disease Stocks Recent News

        Date Stock Title
        Nov 8 IONS Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 7 IONS Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
        Nov 7 IONS A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
        Nov 7 IONS Company News for Nov 7, 2024
        Nov 7 IONS Ionis announces design for Phase III trial of Angelman syndrome therapy
        Nov 7 IONS Q3 2024 Ionis Pharmaceuticals Inc Earnings Call
        Nov 7 IONS Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...
        Nov 6 IONS Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
        Nov 6 IONS Ionis reaches agreement on phase 3 trial design for Angelman candidate
        Nov 6 IONS Ionis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
        Nov 6 IONS Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
        Nov 6 IONS Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
        Nov 6 IONS Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
        Nov 6 IONS Ionis Pharmaceuticals: Q3 Earnings Snapshot
        Nov 6 IONS Ionis Pharmaceuticals GAAP EPS of -$0.95 beats by $0.21, revenue of $134M beats by $4.07M
        Nov 6 IONS Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
        Nov 6 IONS Ionis reports third quarter 2024 financial results
        Nov 5 IONS Ionis Pharmaceuticals Q3 2024 Earnings Preview
        Nov 4 IONS Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
        Nov 4 IONS Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
        Related Industries: Biotechnology
        Related Stock Lists: Rare Diseases Acromegaly Alcohol Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Cancer Cannabinoid Cannabis Cardiomyopathy Cholesterol Cushing's Syndrome Dermatology Diabetes Disease Disorders Drug Discovery
        Ocular Disease

        Ocular disease is any disease or disorder that affects the eyes. It can range from minor conditions such as dry eyes to more serious conditions such as glaucoma and macular degeneration. Common symptoms of ocular disease include blurred vision, redness, pain, and sensitivity to light. Treatment for ocular disease depends on the type and severity of the condition.

        Browse All Tags